Welcome to NBHL
NB Health Laboratory Co. Ltd. (NBHL) is a biotechnology company dedicated to discovering, developing and commercializing innovative medicines to treat respiratory diseases, chronic inflammation and central nervous system disorders. NBHL has expertise in the generation of functional antibodies targeting G protein-coupled receptors (GPCRs) and is pioneering a new field in GPCR-targeted drug discovery to benefit human health.

News archivesALL

  • Completion of the Series C funding to advance pipeline of novel GPCR antibodies Apr 27,2022 -- Updated 22:50 +0900 (GMT)

    NBHL has completed 7.64 million USD of the Series C funding to advance pipeline of novel GPCR antibodies.

    Click here for detail.

  • Announcement of a grant of patent for innovative new high-throughput single-cell analysis technology in US 2022.03.29. Mar 31,2022 -- Updated 10:20 +0900 (GMT)

    We are pleased to inform you that the patent we applied for the new drug candidate search technology has been granted in the United States.

    This patent is regarding a technique for selecting cells that produce a target substance that specifically binds to a cell membrane protein more quickly and efficiently, and a technique relating to a novel single-cell analysis technology (Rapid isolation of GPCR-specific Antibody by Single-cell Screening System: RiGRASSTM) that produces target substances such as antibodies using cells selected by foregoing technology.

    [US Patent Application Number] US 17 / 431,268

    [Public number] WO2020 / 171020

    [Assessment date] March 24, 4th year of Reiwa (2022.3.24)

    [Title of the invention]

    Method for selecting cells, method for producing nucleic acid, method for producing recombinant cells, method for producing target substance, method for producing pharmaceutical composition, and reagent

    We are now able to evaluate antibodies that specifically bind to the G protein-coupled receptor (GPCR) targeted for drug discovery in a shorter period of time than more antibody-producing B cells. We will continue to promote the development of therapeutic agents for antibodies that bind to and act on GPCRs, which have been said to be difficult to obtain.